Top

Arthritis Research & Therapy

Published in:

Open Access 01-06-2011 | Research article

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Authors: Deena A Abdulahad, Johanna Westra, Johannes Bijzet, Pieter C Limburg, Cees GM Kallenberg, Marc Bijl

Published in: Arthritis Research & Therapy | Issue 3/2011

Abstract

Introduction

High Mobility Group Box 1 (HMGB1) is a nuclear non-histone protein. HMGB1, which is secreted by inflammatory cells and passively released from apoptotic and necrotic cells, may act as a pro-inflammatory mediator. As apoptotic cells accumulate in systemic lupus erythematosus (SLE), HMGB1 levels might be increased in SLE. HMGB1 may also serve as an autoantigen, leading to the production of anti-HMGB1 antibodies. In this study we determined levels of HMGB1 and anti-HMGB1 in SLE patients in comparison to healthy controls (HC) and analysed their relation with disease activity.

Methods

The study population consisted of 70 SLE patients and 35 age- and sex-matched HC. Thirty-three SLE patients had quiescent disease, the other 37 patients were selected for having active disease. Nineteen of these had lupus nephritis. HMGB1 levels were measured with both Western blot and ELISA. Anti-HMGB1 levels were measured by ELISA. Clinical and serological parameters were assessed according to routine procedures.

Results

HMGB1 levels in SLE patients could be measured reliably by Western blotting only, and were significantly increased compared to HC. During active disease HMGB1 levels increased, in particular in patients with renal involvement. Serum HMGB1 levels correlated with SLEDAI, proteinuria, and anti-dsDNA levels, and showed a negative correlation with complement C3. Anti-HMGB1 levels were significantly increased in SLE patients compared to HC, and positively correlated with HMGB1 levels.

Conclusions

Levels of HMGB1 in the sera of SLE patients, in particular in those with active renal disease, are increased. Serum HMGB1 levels are related to SLEDAI scores and proteinuria, as well as to levels of anti-HMGB1 antibodies. These findings suggest that besides HMGB1, HMGB1-anti-HMGB1 immune complexes play a role in the pathogenesis of SLE, in particular in patients with renal involvement.

Available only for authorised users

Shirai T, Hirose S: Molecular pathogenesis of SLE. Springer Semin Immunopathol. 2006, 28: 79-82. 10.1007/s00281-006-0032-5.CrossRefPubMed

Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M: HMGB1 in systemic lupus erythematosus: Its role in cutaneous lesions development. Autoimmun Rev. 2010, 9: 661-665. 10.1016/j.autrev.2010.05.015.CrossRefPubMed

Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R: FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol. 2006, 177: 7287-7295.CrossRefPubMed

Schroeter AL, Conn DL, Jordon RE: Immunoglobulin and complement deposition in skin of rheumatoid arthritis and systemic lupus erythematosus patients. Ann Rheum Dis. 1976, 35: 321-326. 10.1136/ard.35.4.321.PubMedCentralCrossRefPubMed

Tokumoto M, Fukuda K, Shinozaki M, Kashiwagi M, Katafuchi R, Yoshida T, Yanagida T, Kanai H, Hirakata H, Tamaki K, Okuda S, Fujishima M: Acute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane. Nephrol Dial Transplant. 1999, 14: 2210-2215. 10.1093/ndt/14.9.2210.CrossRefPubMed

Ehrenstein MR: Antinuclear antibodies and lupus: causes and consequences. Rheumatology (Oxford). 1999, 38: 691-693. 10.1093/rheumatology/38.8.691.CrossRef

Su Y, Jia RL, Han L, Li ZG: Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol. 2007, 122: 115-120. 10.1016/j.clim.2006.10.003.CrossRefPubMed

Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Herrmann M: Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002, 46: 191-201. 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K.CrossRefPubMed

Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG: Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006, 65: 57-63. 10.1136/ard.2005.035733.PubMedCentralCrossRefPubMed

10.

Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994, 179: 1317-1330. 10.1084/jem.179.4.1317.CrossRefPubMed

11.

Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007, 81: 1-5.CrossRefPubMed

12.

Harris HE, Raucci A: Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006, 7: 774-778.PubMedCentralPubMed

13.

Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003, 101: 2652-2660. 10.1182/blood-2002-05-1300.CrossRefPubMed

14.

Hreggvidsdottir HS, Ostberg T, Wahamaa H, Schierbeck H, Aveberger AC, Klevenvall L, Palmblad K, Ottosson L, Andersson U, Harris HE: The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol. 2009, 86: 655-662. 10.1189/jlb.0908548.CrossRefPubMed

15.

Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susarla S, Czura C, Mitchell RA, Chen G, Sama AE, Tracey KJ, Wang H: IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol. 2003, 170: 3890-3897.CrossRefPubMed

16.

Wahamaa H, Vallerskog T, Qin S, Lunderius C, LaRosa G, Andersson U, Harris HE: HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J Leukoc Biol. 2007, 81: 129-136.CrossRefPubMed

17.

Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery. 1999, 126: 389-392. 10.1016/S0039-6060(99)70182-0.CrossRefPubMed

18.

Bell CW, Jiang W, Reich CF, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 2006, 291: C1318-C1325. 10.1152/ajpcell.00616.2005.CrossRefPubMed

19.

Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002, 418: 191-195. 10.1038/nature00858.CrossRefPubMed

20.

Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005, 61: 1-9. 10.1111/j.0300-9475.2005.01534.x.CrossRefPubMed

21.

Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ: A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA. 2010, 107: 11942-11947. 10.1073/pnas.1003893107.PubMedCentralCrossRefPubMed

22.

Park JS, Svetkauskatie D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E: Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004, 279: 7370-7377.CrossRefPubMed

23.

Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007, 8: 487-496.CrossRefPubMed

24.

Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M: Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2006, 54: 2289-2294. 10.1002/art.21969.CrossRefPubMed

25.

Taira T, Matsuyama W, Mitsuyama H, Kawahara KI, Higashimoto I, Maruyama I, Osame M, Arimura K: Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin Exp Immunol. 2007, 148: 241-247. 10.1111/j.1365-2249.2007.03347.x.PubMedCentralCrossRefPubMed

26.

Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003, 48: 971-981. 10.1002/art.10859.CrossRefPubMed

27.

Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE: Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008, 205: 3007-3018. 10.1084/jem.20081165.PubMedCentralCrossRefPubMed

28.

Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S: Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol. 2009, 19: 283-292. 10.1007/s10165-009-0151-7.CrossRefPubMed

29.

Li J, Xie H, Wen T, Liu H, Zhu W, Chen X: Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol. 2010, 37: 766-775. 10.3899/jrheum.090663.CrossRefPubMed

30.

Kocsis AK, Szabolcs A, Hofner P, Takacs T, Farkas G, Boda K, Mandi Y: Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology. 2009, 9: 383-391. 10.1159/000181172.CrossRefPubMed

31.

Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F: Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis. 2010, 69: 1888-1889. 10.1136/ard.2009.119172.CrossRefPubMed

32.

Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE: Factors masking HMGB1 in human serum and plasma. J Leukoc Biol. 2007, 81: 67-74.CrossRefPubMed

33.

Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR: Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int. 2010, 10: 1636-1636.

34.

Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T, Yamada S, Nagayama S, Hashiguchi K, Sunahara N, Fukuzaki K, Nagata R, Komiya S, Maruyama I, Fukuda T, Abeyama K: Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum. 2008, 58: 2675-2685. 10.1002/art.23729.CrossRefPubMed

35.

Steenvoorden MM, Toes RE, Ronday HK, Huizinga TW, Degroot J: RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro. Clin Exp Rheumatol. 2007, 25: 740-742.PubMed

36.

Zuo XX, Zhou YO, Gong YH, Wang YP, Tang DL, Xiao XZ: Expression of high mobility group box chromosomal protein 1 in peripheral blood of patients with rheumatoid arthritis. Zhonghua Nei Ke Za Zhi. 2007, 46: 547-550.PubMed

37.

Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ: High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med. 2008, 14: 109-115. 10.1007/s00894-007-0256-x.PubMedCentralCrossRefPubMed

38.

Oyama Y, Hashiguchi T, Taniguchi N, Tancharoen S, Uchimura T, Biswas KK, Kawahara K, Nitanda T, Umekita Y, Lotz M, Maruyama I: High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest. 2010, 90: 853-866. 10.1038/labinvest.2010.64.PubMedCentralCrossRefPubMed

39.

Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C: Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett. 2008, 121: 61-73. 10.1016/j.imlet.2008.08.007.PubMedCentralCrossRefPubMed

40.

Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I: High Mobility Group Box-1 protein (HMGB) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med. 2010, 17: 29-35.PubMedCentralPubMed

41.

Sato F, Maruyama S, Hayashi H, Sakamoto I, Yamada S, Uchimura T, Morita Y, Ito Y, Yuzawa Y, Maruyama I, Matsuo S: High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract. 2008, 108: c194-c201. 10.1159/000118942.CrossRefPubMed

42.

Mao SY, Xu Y, Zhang J, Schifferli K, An LL, Leininger J, Kiener P, Wu H, Coyle AJ, Audoly LP: Antagonizing HMGB1 inhibits proteinuria in a murine model of lupus like disease (abstract). J Immunol. 2008, 178: 131-124.

Title: High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
Authors: Deena A Abdulahad
Johanna Westra
Johannes Bijzet
Pieter C Limburg
Cees GM Kallenberg
Marc Bijl
Publication date: 01-06-2011
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 3/2011
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar3332

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Abstract

Introduction

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study

Regulation of bone by the adaptive immune system in arthritis

Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model

Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides

Nociceptive tolerance is improved by bradykinin receptor B1 antagonism and joint morphology is protected by both endothelin type A and bradykinin receptor B1 antagonism in a surgical model of osteoarthritis

Novel multiplex technology for diagnostic characterization of rheumatoid arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page